Michael Wang Selected Research

carfilzomib

1/2020	A phase I study of carfilzomib in combination with ibrutinib for relapsed refractory mantle cell lymphoma.
1/2019	A phase II study of carfilzomib in the treatment of relapsed/refractory mantle cell lymphoma.
1/2018	Response and progression-free survival according to planned treatment duration in patients with relapsed multiple myeloma treated with carfilzomib, lenalidomide, and dexamethasone (KRd) versus lenalidomide and dexamethasone (Rd) in the phase III ASPIRE study.
1/2016	Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myeloma.
1/2015	Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma.
1/2015	Serum free light chain reduction correlates with response and progression-free survival following carfilzomib therapy in relapsed/refractory multiple myeloma.
8/2014	Phase 1 study of twice-weekly ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma patients.
12/2013	Overview and management of cardiac and pulmonary adverse events in patients with relapsed and/or refractory multiple myeloma treated with single-agent carfilzomib.
11/2013	In vitro and in vivo therapeutic efficacy of carfilzomib in mantle cell lymphoma: targeting the immunoproteasome.
10/2013	Phase 2 dose-expansion study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Michael Wang Research Topics

Disease

91	Mantle-Cell Lymphoma (Lymphoma, Mantle Cell) 03/2024 - 02/2005
65	Neoplasms (Cancer) 07/2023 - 05/2003
52	Multiple Myeloma 01/2020 - 10/2003
26	B-Cell Lymphoma (Lymphoma, B Cell) 01/2024 - 02/2005
22	Hemorrhage 05/2024 - 05/2003
21	Hemophilia A (Haemophilia) 04/2024 - 01/2013
19	Lymphoma (Lymphomas) 01/2024 - 02/2005
13	Non-Hodgkin Lymphoma (Lymphosarcoma) 12/2023 - 10/2004
9	Follicular Lymphoma (Lymphoma, Small Cleaved Cell, Follicular) 01/2021 - 02/2005
9	Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse) 01/2019 - 05/2013
8	Infections 04/2024 - 07/2003
8	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 01/2022 - 02/2005
7	Disease Progression 07/2023 - 10/2010
7	Thrombosis (Thrombus) 10/2021 - 01/2002
5	Body Weight (Weight, Body) 01/2023 - 05/2016
5	Pain (Aches) 07/2022 - 11/2006
5	Congenital Abnormalities (Deformity) 12/2021 - 10/2015
5	Venous Thromboembolism 10/2012 - 11/2007
4	Peripheral Nervous System Diseases (PNS Diseases) 05/2014 - 06/2009
3	Hemophilia B (Haemophilia B) 01/2024 - 11/2020
3	Necrosis 07/2023 - 01/2002
3	Residual Neoplasm 01/2023 - 01/2019
3	Hodgkin Disease (Hodgkin's Disease) 01/2022 - 11/2006
3	Thrombophilia 10/2021 - 06/2013
3	Dehydration (Water Stress) 01/2020 - 01/2019
3	Neoplasm Metastasis (Metastasis) 01/2019 - 05/2007
3	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 01/2018 - 10/2010
3	Hematologic Neoplasms (Hematological Malignancy) 01/2018 - 11/2011
3	Carcinogenesis 01/2018 - 05/2003
3	Thrombocytopenia (Thrombopenia) 01/2017 - 10/2012
3	Neutropenia 01/2017 - 11/2007
3	Brain Neoplasms (Brain Tumor) 11/2013 - 05/2007
3	Venous Thrombosis (Deep-Vein Thrombosis) 06/2013 - 02/2011
2	von Willebrand Diseases (von Willebrand's Disease) 05/2024 - 01/2022
2	Inflammation (Inflammations) 11/2023 - 10/2021
2	Glioma (Gliomas) 07/2023 - 07/2023
2	Prostatic Neoplasms (Prostate Cancer) 07/2023 - 07/2011
2	Hypersensitivity (Allergy) 07/2022 - 11/2021
2	Waldenstrom Macroglobulinemia (Macroglobulinemia) 01/2022 - 06/2015

Drug/Important Bio-Agent (IBA)

27	ibrutinibIBA 01/2024 - 06/2013
26	Rituximab (Mabthera)FDA Link 01/2023 - 10/2005
24	Lenalidomide (CC 5013)FDA Link 01/2023 - 10/2007
24	Bortezomib (Velcade)FDA Link 11/2019 - 02/2005
23	Agammaglobulinaemia Tyrosine KinaseIBA 02/2024 - 09/2014
18	Chimeric Antigen ReceptorsIBA 12/2023 - 01/2016
17	Dexamethasone (Maxidex)FDA LinkGeneric 01/2020 - 10/2003
15	Proteins (Proteins, Gene)FDA Link 01/2024 - 05/2003
14	carfilzomibIBA 01/2020 - 06/2012
10	Cyclophosphamide (Cytoxan)FDA LinkGeneric 01/2018 - 11/2008
9	Cytarabine (Cytosar-U)FDA LinkGeneric 01/2023 - 10/2005
9	Monoclonal AntibodiesIBA 01/2023 - 10/2006
9	Proteasome InhibitorsIBA 02/2017 - 02/2005
8	Factor VIII (Coagulation Factor VIII)IBA 04/2024 - 02/2011
7	brexucabtagene autoleucelIBA 02/2024 - 01/2020
7	AntibodiesIBA 07/2022 - 04/2008
7	Methotrexate (Mexate)FDA LinkGeneric 01/2018 - 10/2005
7	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2018 - 11/2006
7	Vincristine (Oncovin)FDA LinkGeneric 01/2018 - 11/2008
7	Thalidomide (Thalomid)FDA Link 08/2014 - 10/2003
6	AntigensIBA 09/2023 - 09/2007
6	zanubrutinibIBA 09/2023 - 01/2019
6	acalabrutinibIBA 07/2023 - 01/2018
6	venetoclaxIBA 01/2023 - 01/2018
5	Biomarkers (Surrogate Marker)IBA 11/2022 - 11/2013
4	BESIBA 05/2024 - 01/2022
4	Factor IX (Coagulation Factor IX)FDA LinkGeneric 01/2024 - 01/2017
4	recombinant FVIIa (rFVIIa)FDA Link 07/2022 - 07/2013
4	axicabtagene ciloleucelIBA 01/2022 - 01/2020
4	Cyclin D1IBA 01/2019 - 02/2008
4	Prednisone (Sone)FDA LinkGeneric 01/2018 - 12/2013
4	Antineoplastic Agents (Antineoplastics)IBA 02/2017 - 05/2012
4	Proteasome Endopeptidase Complex (Proteasome)IBA 01/2016 - 07/2006
4	Melphalan (Alkeran)FDA LinkGeneric 05/2012 - 12/2008
3	VaccinesIBA 09/2023 - 10/2009
3	CytokinesIBA 01/2020 - 01/2018
3	Interleukin-6 (Interleukin 6)IBA 01/2020 - 03/2011
3	Anti-Bacterial Agents (Antibiotics)IBA 01/2019 - 01/2014
3	azaspiraneIBA 03/2012 - 06/2007
2	Valoctocogene RoxaparvovecIBA 04/2024 - 01/2023
2	AlbuminsIBA 01/2024 - 09/2014
2	Phosphatidylinositols (Phosphatidylinositol)IBA 07/2023 - 12/2012
2	Phosphotransferases (Kinase)IBA 07/2023 - 11/2016
2	Hemostatics (Antihemorrhagics)IBA 07/2023 - 01/2017
2	von Willebrand FactorIBA 07/2023 - 01/2022
2	ChemokinesIBA 07/2023 - 10/2018
2	pirtobrutinibIBA 01/2023 - 01/2021
2	human F8 protein FDA Link 01/2023 - 08/2020
2	Neutralizing AntibodiesIBA 01/2023 - 11/2006
2	Factor VII (Proconvertin)IBA 07/2022 - 11/2021

Therapy/Procedure

83	Therapeutics 02/2024 - 02/2005
23	Drug Therapy (Chemotherapy) 01/2023 - 10/2004
9	Radiotherapy 05/2019 - 05/2007
8	Immunotherapy 11/2022 - 09/2007
6	Aftercare (After-Treatment) 01/2023 - 10/2005
6	Hematopoietic Stem Cell Transplantation 01/2016 - 12/2008
5	Stem Cell Transplantation 01/2023 - 09/2007
4	Decompression 12/2021 - 11/2010
4	Minimally Invasive Surgical Procedures 07/2019 - 10/2017
3	Transplantation 01/2023 - 11/2010
2	Re-Irradiation 07/2023 - 07/2023